NeuVasQ is a spin-off company from the University of Brussels aiming to repair neurovascular function in a range of disorders by restoring the integrity of the blood-brain barrier.
The blood-brain barrier (BBB) regulates the exchange between the vascular system and central nervous system (CNS). Increased BBB permeability, due to age or injury, is involved in many neurological conditions through the leakage of harmful blood substances into the CNS. BBB dysfunction is a factor in many neurodegenerative disorders, such as Alzheimer’s, as well as multiple acute neurological conditions like stroke and epilepsy.
The company’s approach involves precisely targeting the pathways responsible for BBB formation, with the aim to restore lost functionality to the neurovasculature. NeuVasQ plans to further develop this targeted approach.
The company’s current focus is to identify the most promising indications for clinical trials, focusing on a range of neurodegenerative disorders and acute neurological disorders. As part of these exploratory studies, NeuVasQ will also consider various therapeutic modalities, including gene and mRNA therapy.
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies …
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness …
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the …
Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer. The company is built …
